<DOC>
	<DOCNO>NCT01171690</DOCNO>
	<brief_summary>This study evaluate effect teriparatide ( Forteo ) low calcium level set thyroid surgery associate low parathyroid hormone . The hypothesis teriparatide ( Forteo ) would shorten length hospitalization post thyroidectomy patient symptomatic hypoparathyroidism .</brief_summary>
	<brief_title>Teriparatide Postsurgical Hypoparathyroidism</brief_title>
	<detailed_description>Transient hypoparathyroidism hypocalcemia occur 20 % patient surgery thyroid cancer , multinodular goiter Graves ' disease severe around 3 18 % case . Severe hypocalcemia significantly lengthen hospital stay . This study evaluate effect teriparatide ( synthetic parathyroid hormone , brand name Forteo ) low calcium level set thyroid surgery associate low parathyroid hormone . This feasibility open-label , single-arm trial historical match control plan enrollment 15 patient severe , symptomatic hypocalcemia would treat teriparatide maximum duration 3 week compare active subject 30 gender age match control . Therapy hypocalcemia continue accordance current practice . The decision discharge , far calcium concerned , reach calcium level &gt; 7.5 mg/dL increase x 2 12 hour asymptomatic patient stable therapy need IV calcium last 24 hour . Subjects follow phone blood test 2 day discharge 9 , 17 25 day initiation teriparatide . They teriparatide 24 hour prior test day 9 , 17 25 . If hypocalcemia recur 2nd week , teriparatide continue 3rd week discontinue . If hypocalcemia recur current standard therapy hypoparathyroidism continue teriparatide .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Inclusion criterion : Patients post bilateral thyroid bed surgery ( cancer , Graves disease , multinodular goiter ) Symptomatic hypocalcemia Total calcium &lt; 8 mg/dL persist 24 hour therapy calcitriol ( minimum 0.25 mcg twice day ) calcium supplementation ( minimum 1.5 gram elemental calcium per day ) Parathyroid hormone ( PTH ) level low end normal range Exclusion criterion ( subject ) : Renal failure Any prior parathyroid pathology Preexisting hypercalcemia Metabolic bone diseases osteoporosis Pagets disease Exclusion criterion ( active treatment subject ) : Ongoing therapy Forteo osteoporosis Active nonthyroidal malignancy suspicion residual thyroid malignancy History skeletal malignancy , primary metastatic Pregnancy Active recent urolithiasis Digitalis therapy Patients increase baseline risk osteosarcoma , i.e. , family history osteosarcoma prior radiation therapy involve skeleton Pediatric population Unexplained elevation alkaline phosphatase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hypoparathyroidism</keyword>
</DOC>